Literature DB >> 18989122

Ependymomas of the adult: molecular biology and treatment.

Roberta Rudà1, Mark Gilbert, Riccardo Soffietti.   

Abstract

PURPOSE OF REVIEW: To review state of art and relevant advances in the molecular biology and management of ependymomas of the adult. RECENT
FINDINGS: Ependymomas of the adult are uncommon neoplasms of the central nervous system, and may occur either in the brain or the spinal cord. Compared with intracranial ependymomas, spinal ependymomas are less frequent and exhibit a better prognosis. Studies performed on genetic changes in ependymoma provide some insight into the pathogenesis and prognostic markers and yield new therapeutic targets, particularly focused on signal transduction modulators. The majority of studies have shown a major impact of extent of resection; thus, a complete resection must be performed, whenever possible, at first surgery or at reoperation. Involved field radiotherapy is recommended for anaplastic or incompletely resected grade II tumors. Craniospinal irradiation is reserved for metastatic disease. Chemotherapy is not advocated as primary treatment, and is best utilized as salvage treatment for patients failing surgery and radiotherapy.
SUMMARY: Owing to the rarity of the disease, the literature regarding ependymomas in adults is scarce and limited to retrospective series. Thus, the level of evidence regarding therapeutic strategies is low and universally accepted guidelines are lacking. Molecular biology studies suggest some potential new therapeutic targets.

Entities:  

Mesh:

Year:  2008        PMID: 18989122     DOI: 10.1097/WCO.0b013e328317efe8

Source DB:  PubMed          Journal:  Curr Opin Neurol        ISSN: 1350-7540            Impact factor:   5.710


  32 in total

1.  Uterine Cervix Metastasis of Myxopapillary Ependymoma Originated from the Spinal Cord.

Authors:  Kadir Güzin; Halenur Bozdağ; Abdullah Aydın; Sadık Şahin; Şeyma Özkanlı
Journal:  Balkan Med J       Date:  2016-03-01       Impact factor: 2.021

2.  Ependymoma: current treatment options and a look to the future.

Authors:  Riccardo Soffietti
Journal:  CNS Oncol       Date:  2013-05

Review 3.  Ependymomas in adults.

Authors:  Mark R Gilbert; Roberta Ruda; Riccardo Soffietti
Journal:  Curr Neurol Neurosci Rep       Date:  2010-05       Impact factor: 5.081

4.  Evaluation of chromosome 1q gain in intracranial ependymomas.

Authors:  Madhu Rajeshwari; Mehar Chand Sharma; Aanchal Kakkar; Aruna Nambirajan; Vaishali Suri; Chitra Sarkar; Manmohan Singh; Ravindra Kumar Saran; Rakesh Kumar Gupta
Journal:  J Neurooncol       Date:  2016-01-02       Impact factor: 4.130

5.  Adjuvant radiotherapy delays recurrence following subtotal resection of spinal cord ependymomas.

Authors:  Michael C Oh; Michael E Ivan; Matthew Z Sun; Gurvinder Kaur; Michael Safaee; Joseph M Kim; Eli T Sayegh; Derick Aranda; Andrew T Parsa
Journal:  Neuro Oncol       Date:  2012-12-09       Impact factor: 12.300

Review 6.  Brain tumors across the age spectrum: biology, therapy, and late effects.

Authors:  Thomas E Merchant; Ian F Pollack; Jay S Loeffler
Journal:  Semin Radiat Oncol       Date:  2010-01       Impact factor: 5.934

7.  A pilot study on the use of cerebrospinal fluid cell-free DNA in intramedullary spinal ependymoma.

Authors:  Ian David Connolly; Yingmei Li; Wenying Pan; Eli Johnson; Linya You; Hannes Vogel; John Ratliff; Melanie Hayden Gephart
Journal:  J Neurooncol       Date:  2017-09-12       Impact factor: 4.130

Review 8.  Spinal cord tumours: advances in genetics and their implications for treatment.

Authors:  Patricia L Zadnik; Ziya L Gokaslan; Peter C Burger; Chetan Bettegowda
Journal:  Nat Rev Neurol       Date:  2013-03-26       Impact factor: 42.937

9.  Temozolomide as salvage treatment for recurrent intracranial ependymomas of the adult: a retrospective study.

Authors:  Roberta Rudà; Chiara Bosa; Michela Magistrello; Federica Franchino; Alessia Pellerino; Valentina Fiano; Morena Trevisan; Paola Cassoni; Riccardo Soffietti
Journal:  Neuro Oncol       Date:  2015-08-30       Impact factor: 12.300

10.  Lower urinary tract symptoms: thinking beyond the urinary tract.

Authors:  Akbar Ashrafi; David Winkle
Journal:  BMJ Case Rep       Date:  2014-07-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.